Session » RA – Etiology & Pathogenesis Poster (0011–0045)

Date: Saturday, November 6, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0031

A New Pharmacostatistical Model to Assess MTX-adherence in RA Patients

8:30AM-10:30AM: Abstract Number: 0012

A Novel Mechanism Linking Mucosal Bacteria with Autoantibody Responses in RA: Acetylated Bacterial Lysate as a Model Antigen

8:30AM-10:30AM: Abstract Number: 0038

Arthritis Progression in at Risk Individuals Is Associated with ACPAs Not AMPAs

8:30AM-10:30AM: Abstract Number: 0044

Autoantibodies Against Malondialdehyde-modifications Promote Osteoclast Development by Reprogramming Cellular Metabolism

8:30AM-10:30AM: Abstract Number: 0035

Bromodomain Protein-regulated Stress Response in Rheumatoid Arthritis Synovial Fibroblasts

8:30AM-10:30AM: Abstract Number: 0018

Caspase-8 Variant G Regulates Rheumatoid Arthritis Fibroblast-Like Synoviocyte Aggressive Behavior

8:30AM-10:30AM: Abstract Number: 0020

Citrullination Drives the Expression of Pro-fibrotic Genes in Rheumatoid Arthritis Fibroblast-like Cells

8:30AM-10:30AM: Abstract Number: 0013

Cyclin Dependent Kinase 4 and 6 Determine the Cytokine Responsiveness by Stabilizing JUN in Rheumatoid Arthritis Synovial Fibroblasts

8:30AM-10:30AM: Abstract Number: 0011

Differential Inflammation-mediated Function of Prokineticin 2 in the Synovial Fibroblasts of Patients with Rheumatoid Arthritis Compared to Osteoarthritis

8:30AM-10:30AM: Abstract Number: 0039

Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?

8:30AM-10:30AM: Abstract Number: 0045

Endothelial Cells from Patients with DMARD Naïve, Active Inflammatory Arthritis Demonstrate Pro-inflammatory Sensitisation That Is Reversed by Therapy Initiation

8:30AM-10:30AM: Abstract Number: 0028

Evolution of Anti-modified Protein Antibody Responses Can Be Driven by Consecutive Exposure to Different Post-translational Modifications

8:30AM-10:30AM: Abstract Number: 0024

Heterogeneity of Inflammatory HLA-DR+ Synovial Fibroblasts in Rheumatoid Arthritis Is Driven by Responses to Leukocyte-Derived Cytokines

8:30AM-10:30AM: Abstract Number: 0042

High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0037

Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0032

IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis

8:30AM-10:30AM: Abstract Number: 0034

Immune Complexes Contain Novel Acetylated Antigens in the Synovial Fluid of RA Patients

8:30AM-10:30AM: Abstract Number: 0033

Impaired Adipose Tissue Function in Rheumatoid Arthritis: Association with Autoimmunity, Disease Activity and Therapeutic Response

8:30AM-10:30AM: Abstract Number: 0019

Increased Circulating CD39+FoxP3+CD4+ Treg Cells in Early Rheumatoid Arthritis Facilitate the Antiinflammatory Action of Methotrexate

8:30AM-10:30AM: Abstract Number: 0030

Interleukin-9 Enhances the Osteoclastogenesis in Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0023

Investigating Temporal Changes in Pregnancy Among Women with Rheumatoid Arthritis and Healthy Women Using Co-expression Network Analysis

8:30AM-10:30AM: Abstract Number: 0029

JAK1 Regulates Autophagy and Reinforces the Inflammatory and Autoimmune Potentials in Rheumatoid Arthritis Synovial Fibroblasts

8:30AM-10:30AM: Abstract Number: 0017

Lessons Learnt from Associations Between Anti-modified Protein Antibodies and Risk Factors: Human Leukocyte Antigen – Shared Epitope Alleles Solely Associate with Anti-citrullinated Protein Antibodies

8:30AM-10:30AM: Abstract Number: 0014

Low Baseline Expression of Pyruvate Kinase and Succinate Dehydrogenase Genes in the Peripheral Blood of Rheumatoid Arthritis Patients Treated with Tofacitinib Is Associated with Clinical Remission at the End of Follow-up

8:30AM-10:30AM: Abstract Number: 0040

M1-M2 Polarization by CTLA4-Ig (Abatacept) on Cultured Circulating Monocytes from Rheumatoid Arthritis Patients and Healthy Subjects

8:30AM-10:30AM: Abstract Number: 0027

Metabolomic Study of Rheumatoid Arthritis Using 1H Nuclear Magnetic Resonance (1H NMR)

8:30AM-10:30AM: Abstract Number: 0015

Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules

8:30AM-10:30AM: Abstract Number: 0016

Structural and Functional Neurobiological Alterations of Salience and Sensorimotor Networks in Juvenile Idiopathic Arthritis

8:30AM-10:30AM: Abstract Number: 0026

Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1)

8:30AM-10:30AM: Abstract Number: 0043

Takinib Inhibits IL-1β-Induced Activation of Signal Transducer and Activator of Transcription 3 (STAT3) in Human Rheumatoid Arthritis Synovial Fibroblasts

8:30AM-10:30AM: Abstract Number: 0022

The Effects of MAA-Modified and/or Citrullinated Proteins on Calcium Influx and Peptidyl Arginine Deiminase (PAD) Expression in Macrophage

8:30AM-10:30AM: Abstract Number: 0025

The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0036

The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects

8:30AM-10:30AM: Abstract Number: 0021

Unique Alterations in Circulating T Peripheral Helper Cells Are Found in Different Ethnic Groups of ACPA+ Individuals Both At-risk for and with Classified RA

8:30AM-10:30AM: Abstract Number: 0041

Vascularized ‘Synovium-on-a-Chip’ – A Novel and Adaptable Model for Dissecting Inflammatory Biology Underlying Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].